v3.23.1

Note 2 - Summary of Significant Accounting Policies (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2022
Notes Tables |
Schedule of Error Corrections and Prior Period Adjustments [Table Text Block] |
|  | Reclassification Adjustment |
|  | Three Months Ended |  |  | Year Ended |
|  | March 31, 2021 |  |  | June 30, 2021 |  |  | September 30, 2021 |  |  | December 31, 2021 |  |  | December 31, 2021 |
United States |  | $ | (362 | ) |  | $ | (615 | ) |  | $ | (703 | ) |  | $ | (440 | ) |  | $ | (2,120 | )
International |  |  | 362 |  |  |  | 615 |  |  |  | 703 |  |  |  | 440 |  |  |  | 2,120 |
Total revenue |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | — |
|  | As previously reported |  |  | Adjustment |  |  | As reclassified |
Consolidated statements of operations: |  |  |  |  |  |  |  |  |  |  |  |
For the year ended December 31, 2021 |  |  |  |  |  |  |  |  |  |  |  |
Selling and marketing |  | $ | 37,438 |  |  | $ | 4,482 |  |  | $ | 41,920 |
General and administrative |  |  | 45,940 |  |  |  | (5,870 | ) |  |  | 40,070 |
Research and development |  |  | 8,258 |  |  |  | 1,388 |  |  |  | 9,646 |
Condensed consolidated statements of operations for the three months ended: |  |  |  |  |  |  |  |  |  |  |  |
March 31, 2022 |  |  |  |  |  |  |  |  |  |  |  |
Selling and marketing |  |  | 9,903 |  |  |  | 1,181 |  |  |  | 11,084 |
General and administrative |  |  | 13,094 |  |  |  | (1,622 | ) |  |  | 11,472 |
Research and development |  |  | 2,202 |  |  |  | 441 |  |  |  | 2,643 |
March 31, 2021 |  |  |  |  |  |  |  |  |  |  |  |
Selling and marketing |  |  | 7,854 |  |  |  | 1,052 |  |  |  | 8,906 |
General and administrative |  |  | 12,165 |  |  |  | (1,408 | ) |  |  | 10,757 |
Research and development |  |  | 2,051 |  |  |  | 356 |  |  |  | 2,407 |
June 30, 2022 |  |  |  |  |  |  |  |  |  |  |  |
Selling and marketing |  |  | 9,487 |  |  |  | 1,036 |  |  |  | 10,523 |
General and administrative |  |  | 14,249 |  |  |  | (1,312 | ) |  |  | 12,937 |
Research and development |  |  | 2,436 |  |  |  | 276 |  |  |  | 2,712 |
June 30, 2021 |  |  |  |  |  |  |  |  |  |  |  |
Selling and marketing |  |  | 10,114 |  |  |  | 1,139 |  |  |  | 11,253 |
General and administrative |  |  | 7,828 |  |  |  | (1,468 | ) |  |  | 6,360 |
Research and development |  |  | 2,024 |  |  |  | 329 |  |  |  | 2,353 |
September 30, 2022 |  |  |  |  |  |  |  |  |  |  |  |
Selling and marketing |  |  | 8,094 |  |  |  | 1,275 |  |  |  | 9,369 |
General and administrative |  |  | 14,128 |  |  |  | (1,723 | ) |  |  | 12,405 |
Research and development |  |  | 2,576 |  |  |  | 448 |  |  |  | 3,024 |
September 30, 2021 |  |  |  |  |  |  |  |  |  |  |  |
Selling and marketing |  |  | 8,775 |  |  |  | 1,035 |  |  |  | 9,810 |
General and administrative |  |  | 11,990 |  |  |  | (1,337 | ) |  |  | 10,653 |
Research and development |  |  | 1,930 |  |  |  | 302 |  |  |  | 2,232 |
|  | As previously reported |  |  | Adjustment |  |  | As reclassified |
Consolidated balance sheets: |  |  |  |  |  |  |  |  |  |  |  |
December 31, 2021 |  |  |  |  |  |  |  |  |  |  |  |
Advances to suppliers |  | $ | 2,162 |  |  | $ | 3,505 |  |  | $ | 5,667 |
Trade payables |  |  | 4,913 |  |  |  | 3,505 |  |  |  | 8,418 |
March 31, 2022 |  |  |  |  |  |  |  |  |  |  |  |
Advances to suppliers |  |  | 3,532 |  |  |  | 2,856 |  |  |  | 6,388 |
Trade payables |  |  | 4,788 |  |  |  | 2,856 |  |  |  | 7,644 |
June 30, 2022 |  |  |  |  |  |  |  |  |  |  |  |
Advances to suppliers |  |  | 2,869 |  |  |  | 3,090 |  |  |  | 5,959 |
Trade payables |  |  | 4,184 |  |  |  | 3,090 |  |  |  | 7,274 |
September 30, 2022 |  |  |  |  |  |  |  |  |  |  |  |
Advances to suppliers |  |  | 3,605 |  |  |  | 2,186 |  |  |  | 5,791 |
Trade payables |  |  | 6,093 |  |  |  | 2,186 |  |  |  | 8,279 |
|  | As previously reported |  |  | Adjustment |  |  | As reclassified |
Consolidated statements of cash flows: |  |  |  |  |  |  |  |  |  |  |  |
For the year ended December 31, 2021 |  |  |  |  |  |  |  |  |  |  |  |
Changes in operating assets and liabilities: |  |  |  |  |  |  |  |  |  |  |  |
Advances to suppliers |  | $ | 425 |  |  | $ | (3,505 | ) |  | $ | (3,080 | )
Trade payables |  |  | (1,409 | ) |  |  | 3,505 |  |  |  | 2,096 |
For the three months ended March 31, 2022 |  |  |  |  |  |  |  |  |  |  |  |
Changes in operating assets and liabilities: |  |  |  |  |  |  |  |  |  |  |  |
Advances to suppliers |  |  | (1,370 | ) |  |  | (2,856 | ) |  |  | (4,226 | )
Trade payables |  |  | (125 | ) |  |  | 2,856 |  |  |  | 2,731 |
For the three months ended March 31, 2021 |  |  |  |  |  |  |  |  |  |  |  |
Changes in operating assets and liabilities: |  |  |  |  |  |  |  |  |  |  |  |
Advances to suppliers |  |  | (1,417 | ) |  |  | (1,680 | ) |  |  | (3,097 | )
Trade payables |  |  | (178 | ) |  |  | 1,680 |  |  |  | 1,502 |
For the six months ended June 30, 2022 |  |  |  |  |  |  |  |  |  |  |  |
Changes in operating assets and liabilities: |  |  |  |  |  |  |  |  |  |  |  |
Advances to suppliers |  |  | (707 | ) |  |  | (3,090 | ) |  |  | (3,797 | )
Trade payables |  |  | (729 | ) |  |  | 3,090 |  |  |  | 2,361 |
For the six months ended June 30, 2021 |  |  |  |  |  |  |  |  |  |  |  |
Changes in operating assets and liabilities: |  |  |  |  |  |  |  |  |  |  |  |
Advances to suppliers |  |  | (772 | ) |  |  | (2,291 | ) |  |  | (3,063 | )
Trade payables |  |  | (640 | ) |  |  | 2,291 |  |  |  | 1,651 |
For the nine months ended September 30, 2022 |  |  |  |  |  |  |  |  |  |  |  |
Changes in operating assets and liabilities: |  |  |  |  |  |  |  |  |  |  |  |
Advances to suppliers |  |  | (1,443 | ) |  |  | (2,186 | ) |  |  | (3,629 | )
Trade payables |  |  | 1,180 |  |  |  | 2,186 |  |  |  | 3,366 |
For the nine months ended September 30, 2021 |  |  |  |  |  |  |  |  |  |  |  |
Changes in operating assets and liabilities: |  |  |  |  |  |  |  |  |  |  |  |
Advances to suppliers |  |  | (142 | ) |  |  | (2,500 | ) |  |  | (2,642 | )
Trade payables |  |  | (1,573 | ) |  |  | 2,500 |  |  |  | 927 |

X
- Definition Tabular disclosure of prior period adjustments to previously issued financial statements including (1) the effect of the correction on each financial statement line item and any per-share amounts affected for each prior period presented (2) the cumulative effect of the change on retained earnings or other appropriate components of equity or net assets in the statement of financial position, as of the beginning of the earliest period presented, and (3) the effect of the prior period adjustments (both gross and net of applicable income tax) on the net income of each prior period presented in the entity's annual report for the year in which the adjustments are made. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 9 -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 7 -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 8 -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794 + Details
Name: | us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_TableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration